MENU

Why Pharmaxis is down 45%

Shares of pharmaceutical and biotech company Pharmaxis (ASX: PXS) are down nearly 50% today — and down nearly 87% year to date, compared to a near 10% rise in the S&P/ASX 200 index (Index: ^AXJO) (ASX: XJO). What’s behind this jaw-dropping plunge?

Screen Shot 2013-04-24 at 2.03.50 PM

It seems the drop is down to disappointing results from a late-stage trial of the company’s Bronchitol drug. As The Australian has reported, “Pharmaxis said its Phase III clinical trial of Bronchitol, also referred to as B305, had not shown a significant difference in the rates of pulmonary exacerbations (worsening lung function) in patients treated over a 12-month period.”

Shares were halted following the company’s receiving the news this past Monday, delaying the ugly result until today, when trading resumed.

Chief executive of Pharmaxis Gary Phillips has said that “It is disappointing not to have achieved the primary endpoint in this trial… We will, therefore, not be proceeding immediately with a regulatory submission for bronchiectasis.”

Looking for a far more solid investment ideas? Two of Australia’s most promising small companies are still flying under the radar. Discover these two exciting ASX investments in our brand-new special FREE report, “2 Small Cap Superstars”. Click here now, it’s free!

More reading

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. Motley Fool writer/analyst Catherine Baab-Muguira does not own shares in any of the companies mentioned in this article.

 

 

 

 

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.